Welcome to our dedicated page for Agilent Technologies news (Ticker: A), a resource for investors and traders seeking the latest updates and insights on Agilent Technologies stock.
Agilent Technologies Inc. (NYSE: A) operates at the intersection of scientific instrumentation and laboratory workflows, making its news coverage particularly relevant for investors tracking the life sciences and diagnostics sectors. As a major supplier to pharmaceutical, environmental, and clinical laboratories worldwide, Agilent's announcements often signal broader trends in research spending and healthcare diagnostics.
Key news categories for Agilent include quarterly earnings reports that reveal demand across its three business segments, product launches introducing new chromatography systems, mass spectrometers, and diagnostic assays, and FDA regulatory decisions affecting its companion diagnostics products. The company's pathology and genomics solutions frequently receive clearances that expand clinical testing capabilities.
Investors also monitor Agilent for strategic collaborations with pharmaceutical and biotechnology companies, acquisitions that extend its technology portfolio, and announcements regarding its dividend program. Conference presentations at healthcare investor events provide management perspectives on end-market conditions in biopharma, food testing, and environmental analysis.
Agilent's news flow reflects its position serving regulated industries where instrument qualification, method validation, and compliance software are critical. Product announcements often highlight improvements in analytical sensitivity, throughput, and data integrity features that laboratories require for regulatory submissions.
Bookmark this page to follow Agilent Technologies developments as they happen, from earnings releases and product innovations to partnerships shaping the future of analytical science.
Agilent Technologies (NYSE: A) has launched its new Insight Series Alarm Resolution Systems for airport security screening, featuring the Insight300M and InsightBLS models. These advanced liquid explosive detection systems (LEDs) are designed to screen liquids, aerosols, and gels (LAGs) at airport checkpoints.
The systems boast the industry's lowest false alarm rate and rapid scan times, capable of identifying threats through complex barriers and multi-layered materials. A key feature is their future-proof design, allowing updates through software upgrades without hardware replacement. The launch builds on Agilent's 2017 acquisition of Cobalt Light Systems and will be showcased at the International Security Expo in London.
Agilent Technologies (NYSE: A) has launched the new Altura Ultra Inert HPLC Columns, designed specifically for biotherapeutics applications. The innovative columns demonstrate up to 2x sensitivity and 3x signal-to-noise ratio compared to competitors, while achieving up to 30x higher peak area when used with Agilent's 1290 Infinity III Bio LC.
The Altura line addresses critical needs in biopharma testing, particularly for peptide GLP-1 and oligonucleotide therapeutic development. Early testing shows a 30% increase in sensitivity and reduced peak tailing for acidic peptides and excipients analysis, offering superior chromatographic performance through faster conditioning, improved peak shape, and enhanced sensitivity.
Agilent Technologies (NYSE: A) has announced a nonexclusive collaboration with Lunit (KRX:328130.KQ) to develop AI-powered companion diagnostic solutions. The partnership combines Lunit's artificial intelligence expertise with Agilent's tissue-based diagnostic capabilities to enhance biomarker testing accuracy.
The collaboration will initially focus on developing AI-powered assays for research and clinical trials, integrating Lunit's AI algorithms with Agilent's state-of-the-art assays. The joint solutions aim to support pharmaceutical companies in companion diagnostic product development, potentially accelerating the development of biomarker-driven therapies and improving patient treatment precision.
Agilent Technologies (NYSE: A) has declared a quarterly dividend of 24.8 cents per share of common stock. The dividend will be paid on October 22, 2025, to shareholders of record as of September 30, 2025. Future dividend payments remain subject to board approval.
Agilent Technologies (NYSE: A) announced that President and CEO Padraig McDonnell will participate in a fireside chat at the Bank of America Global Healthcare Conference in London. The presentation is scheduled for September 25, 2025, from 9:50-10:30 AM BST. Investors can access both the live audio webcast and replay through Agilent's Investor Relations website.
Agilent Technologies (NYSE: A) has achieved the highest level of My Green Lab Certification—Green level—at its Refurbishment Centers in Delaware, USA, and Singapore. The centers scored 90% and 87% respectively in rigorous sustainability assessments across 12 critical categories.
The certification highlights Agilent's Certified Pre-Owned (CPO) program, which restores used instruments to factory-grade condition, supporting a circular lab economy through trade-in and buy-back options. Approximately 50% of refurbishment team members have become My Green Lab Ambassadors, demonstrating the company's commitment to sustainability.
TORM plc (NASDAQ: TRMD) announced that Hafnia Limited will acquire approximately 14.1 million A shares (14.45% of TORM's issued share capital) from Oaktree Capital Management. The transaction is valued at USD 22 per share, totaling USD 311.4 million.
The share purchase completion is subject to several conditions, including regulatory approvals, satisfaction of certain covenants, and the appointment of a new independent board chairman. TORM clarified that it was not involved in the transaction and has no additional information at this time.
Agilent Technologies (NYSE: A) announced its participation as a premium sponsor at the European Congress of Pathology (ECP) 2025 in Vienna, Austria, from September 6-10, 2025. The company will showcase the European launch of its expanded Dako Omnis Family of instruments, including the Dako Omnis 110, 165, and 165 Duo models.
The event will feature live demonstrations, expert sessions, and educational symposia focusing on diagnostic excellence and workflow optimization. Visitors can explore Agilent's Digital Pathology solutions and participate in PD-L1 CPS scoring sessions at booth #18.
Agilent Technologies (NYSE: A) has achieved a significant regulatory milestone as its MMR IHC Panel pharmDx (Dako Omnis) received European IVDR certification as a class C companion diagnostic test for colorectal cancer. The panel is specifically designed to identify mismatch repair (MMR) deficient CRC patients who may be eligible for treatment with OPDIVO® in combination with YERVOY®.
The diagnostic panel is uniquely positioned as the only companion diagnostic IHC panel IVDR approved for this specific treatment combination in colorectal cancer patients. The test works by detecting the loss of function in four key MMR proteins (MLH1, PMS2, MSH2, and MSH6) in tissue samples, helping identify patients who may respond better to immunotherapy.
Agilent Technologies (NYSE: A) reported strong Q3 2025 financial results with revenue of $1.74 billion, representing 10.1% reported growth and 6.1% core growth year-over-year. The company achieved GAAP EPS of $1.18 (up 22%) and non-GAAP EPS of $1.37 (up 4%).
All three business segments showed growth: Life Sciences and Diagnostics Markets Group revenue increased 14% to $670 million, Agilent CrossLab Group grew 8% to $744 million, and Applied Markets Group rose 7% to $324 million.
Agilent raised its full-year 2025 outlook, projecting revenue between $6.91-6.93 billion (6.2-6.5% growth) and non-GAAP EPS of $5.56-5.59. Q4 2025 revenue is expected at $1.822-1.842 billion with non-GAAP EPS of $1.57-1.60.
FAQ
What is the current stock price of Agilent Technologies (A)?
What is the market cap of Agilent Technologies (A)?
